LEVOLET (Levothyroxine Sodium) Patent Expiration, LOE Window & CMS Spending

LEVOLET (Levothyroxine Sodium) by Genus Life Sciences: FDA Orange Book core substance LOE 2038-03-23, 7 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGenus Life Sciences
FDA Application & PathwayN021137 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-03-23
Last Listed Patent or Exclusivity Date2038-03-23
Orange Book Patents (*PED Extensions)20 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel